Quoin Pharmaceuticals annual stock-based compensation
2017
2019
2020
2021
2022
2023
2024
2025
Quoin Pharmaceuticals Stock-Based Compensation Growth & History (QNRX)
Quoin Pharmaceuticals's stock-based compensation was $1.1M for fiscal 2025.
View full Quoin Pharmaceuticals company overviewQuoin Pharmaceuticals annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.1M | −$111,654 | −8.87% |
| 2024 | 2024-12-31 | $1.3M | $164,341 | +15.01% |
| 2023 | 2023-12-31 | $1.1M | $330,542 | +43.26% |
| 2022 | 2022-12-31 | $764,007 | $764,007 | — |
| 2021 | 2021-12-31 | $0 | −$229,000 | — |
| 2020 | 2020-12-31 | $229,000 | −$555,000 | −70.79% |
| 2019 | 2019-12-31 | $784,000 | — | — |
| 2017 | 2017-12-31 | $1.6M | — | — |
Quoin Pharmaceuticals quarterly stock-based compensation
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $532,951 | $211,465 | +65.78% |
| Q1 2026 | 2026-03-31 | $444,525 | $84,168 | +23.36% |
| Q4 2025 | 2025-12-31 | $283,205 | −$43,127 | −13.22% |
| Q3 2025 | 2025-09-30 | $182,188 | −$130,934 | −41.82% |
| Q2 2025 | 2025-06-30 | $321,486 | $8,364 | +2.67% |
| Q1 2025 | 2025-03-31 | $360,357 | $54,043 | +17.64% |
| Q4 2024 | 2024-12-31 | $326,332 | $26,134 | +8.71% |
| Q3 2024 | 2024-09-30 | $313,122 | $44,619 | +16.62% |
| Q2 2024 | 2024-06-30 | $313,122 | $48,746 | +18.44% |
| Q1 2024 | 2024-03-31 | $306,314 | $44,842 | +17.15% |
| Q4 2023 | 2023-12-31 | $300,198 | $32,474 | +12.13% |
| Q3 2023 | 2023-09-30 | $268,503 | $1,220 | +0.46% |
| Q2 2023 | 2023-06-30 | $264,376 | $35,376 | +15.45% |
| Q1 2023 | 2023-03-31 | $261,472 | $261,472 | — |
| Q4 2022 | 2022-12-31 | $267,724 | — | — |
| Q3 2022 | 2022-09-30 | $267,283 | — | — |
| Q2 2022 | 2022-06-30 | $229,000 | — | — |
| Q1 2022 | 2022-03-31 | $0 | — | — |
Quoin Pharmaceuticals stock-based compensation trends
Over the last five fiscal years, Quoin Pharmaceuticals's stock-based compensation increased from $229,000 to $1.1M, a change of $918,236. The latest reported quarter, Q2 2026, shows $532,951.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Quoin Pharmaceuticals source filings ↗